CGI vs Nasdaq

8-K Financial Filing Analysis for CGI (2026-11-03)

On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.

• Corcept Therapeutics furnished its Q3 2026 financial results for the period ended September 30, 2026, via an 8-K press release notice on November 3, 2026.
• The disclosure was furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), with Exhibit 99.1 containing the full press release.
• The filing was formally signed and authorized by Chief Financial Officer Atabak Mokari on November 3, 2026.

10-Q Financial Filing Analysis for CGI (2026-11-03)

Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.

• Q3 2026 net product revenue grew 64.0% year-over-year to $340.47M, with newly approved oncology drug Lifyorli contributing $91.41M and hypercortisolism products generating $249.07M.
• Operating income for the quarter reached $114.72M compared to $10.22M in Q3 2025, while diluted earnings per common share expanded to $1.01 compared to $0.16.
• The resubmitted New Drug Application (NDA) for relacorilant in endogenous hypercortisolism has an assigned PDUFA target action date of December 17, 2026.

CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems

CGI has been named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems, a significant industry recognition for the company's trade finance technology leadership.

8-K Financial Filing Analysis for Nasdaq (2026-10-26)

On October 21, 2026, Nasdaq, Inc. elected Börje Ekholm to its Board of Directors, effective November 1, 2026. Mr. Ekholm, the former President and CEO of Ericsson and former CEO of Investor AB, previously served on Nasdaq's Board from 2011 to 2016, including tenure as Chair from 2012 to 2016. He is designated as an independent director and will serve on the Audit & Risk Committee. In addition, on October 22, 2026, director Holden Spaht tendered his resignation from the Board and all committees, effective December 31, 2026, with no disagreements reported.

• Börje Ekholm appointed as independent director and member of the Audit & Risk Committee effective November 1, 2026, having previously served as Nasdaq Board Chair from 2012 to 2016.
• Director Holden Spaht tendered his resignation from the Board and all committees, effective December 31, 2026, without any disagreement with the company.
• Disclosed related-party transaction involving an immediate family member of Ekholm employed at Nasdaq in a non-officer role, earning over $120,000 since fiscal 2025, which was ratified by the Audit & Risk Committee.

8-K Financial Filing Analysis for Nasdaq (2026-10-22)

On October 22, 2026, Nasdaq, Inc. filed a Current Report on Form 8-K to furnish its financial results for the third quarter of 2026 pursuant to Item 2.02. Concurrently, the company posted its Q3 2026 earnings presentation slides to its investor relations website under Item 7.01 and announced under Item 8.01 that its Board of Directors declared a quarterly cash dividend. The filing incorporates the earnings release and dividend announcement as exhibits, serving as the official SEC notification of its quarterly performance and capital return distribution.

• Nasdaq furnished its Q3 2026 operational and financial results via press release on October 22, 2026 (Exhibit 99.1).
• The Board of Directors declared a quarterly cash dividend announced via press release on October 22, 2026 (Exhibit 99.2).
• Q3 2026 investor presentation slides were made publicly accessible on Nasdaq's investor relations website (http://ir.nasdaq.com) under Regulation FD.

Wiener Börse CEO: EU Super Exchange Exists, Lacks Market Depth

In a podcast interview, Christoph Boschan, CEO of Wiener Börse, discusses the debate over a new European stock exchange. He argues that the infrastructure for a 'super exchange' already exists, but the real problem is market depth. He notes that European tech companies like Bending Spoons prefer listing on the Nasdaq due to better access to capital, while US firms are financed through equity, Europe through debt. He suggests that pension policy, not market infrastructure, is the key lever to increase liquidity and attract listings. He also points to record levels of the ATX and the need for faster, tax-friendlier conditions in Europe.

• Christoph Boschan, CEO der Wiener Börse, sagt, die EU-Superbörse existiere bereits, aber es fehle an Markttiefe.
• European tech companies like Bending Spoons prefer listing on the Nasdaq.
• The US finances companies through equity, Europe through debt.